Generic drug maker Mylan’s $26 billion(€24bn) hostile bid for peer Perrigo Company Plc looks, according to people familiar with the matter. If confirmed, the outcome would represent a major victory for Perrigo’s defiant chief executive Joseph Papa, and a bitter blow to Mylan’s executive chairman Robert Coury, who snubbed an acquisition offer from Teva...
↧